Foghorn Therapeutics Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
FHTX Nasdaq 8731 https://foghorntx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Foghorn Therapeutics Inc.

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer - Sep 11th, 2023 10:30 am
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences - Sep 5th, 2023 12:00 pm
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML - Aug 31st, 2023 11:00 am
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology - Aug 29th, 2023 1:00 pm
These Analysts Think Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Sales Are Under Threat - Aug 11th, 2023 7:54 pm
Foghorn Therapeutics Announces Chief Medical Officer Succession - Aug 8th, 2023 11:00 am
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates - Aug 4th, 2023 12:15 pm
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update - Aug 4th, 2023 11:00 am
Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains? - Jul 9th, 2023 11:58 pm
Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer - Jun 28th, 2023 5:44 pm
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma - Jun 28th, 2023 11:00 am
Investors in Foghorn Therapeutics (NASDAQ:FHTX) from a year ago are still down 47%, even after 20% gain this past week - Jun 6th, 2023 11:56 am
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients - Jun 5th, 2023 11:00 am
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry - May 16th, 2023 10:00 am
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely - May 10th, 2023 11:47 am
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates - May 8th, 2023 12:15 pm
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update - May 8th, 2023 11:00 am
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? - Apr 27th, 2023 8:35 am
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference - Apr 25th, 2023 8:05 pm
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold - Apr 24th, 2023 5:28 pm